Epidermal growth factor receptors in non-small cell lung cancer. by Veale, D. et al.
Br. J. Cancer (1987), 55, 513 516 © The Macmillan Press Ltd., 1987
Epidermal growth factor receptors in non-small cell lung cancer
D. Vealel, T. Ashcroft2, C. Marsh2, G.J. Gibson' & A.L. Harris3
Departments of 'Respiratory Medicine and 2Pathology, Freeman Hospital; Cancer Research Unit and 3Department of Clinical
Oncology, Newcastle upon Tyne, UK.
Summary The epidermal growth factor receptor is homologous to the oncogene erb-,B and is the receptor for
a class of tumour growth factors (TGF-ca). The clinical correlations with its expression were studied in 77 non-
small cell lung cancers (NSCLC). They were stained for epidermal growth factor receptor (EGFr) by means of
an indirect immunoperoxidase technique using a monoclonal antibody against the receptor. Normal lung
tissue and normal bronchus were stained for comparison. Cancer tissue showed significantly increased staining
compared to normal lung (P<0.05).
Staining for EGFr in 40 squamous carcinomas was significantly stronger than in 37 specimens of other
types of NSCLC (P<0.05), and staining in stage three NSCLC was stronger than in stage 1 and 2 (P<0.05).
These results suggest that the presence of a high intensity of staining for EGF receptor is associated with
spread of human non-small cell lung cancer and this receptor may be a suitable target for therapy.
Non-small cell lung cancer (NSCLC) comprises pre-
dominantly squamous, adenocarcinomas and large cell un-
differentiated tumours. Only 5% of such tumours are curable
by surgery (Crofton & Douglas, 1981), and up to 60% are
inoperable at the time of diagnosis (Crofton & Douglas,
1981). Chemotherapy is relatively ineffective, with a 17%
response rate and no long-term survival (Simes, 1985).
Radiotherapy also is rarely curative (Kjaer, 1982). Survival in
NSCLC is related to the degree of spread of the tumour at
diagnosis, staged by the tumour nodal involvement
metastasis (TNM) system (Mountain et al., 1974).
A characteristic of malignant cells in culture is a decreased
requirement for serum or supplemental growth factors
(Holley, 1975). This suggests that malignant cells may secrete
growth factors into their medium. Sporn and Todaro (1980)
have suggested the term autocrine growth regulation to
describe the situation where a cell secretes a factor, possesses
specific receptors for the factor and responds to that factor.
Epidermal growth factor (EGF) is a growth promoting
agent found in normal human plasma and tissues which acts
by binding to receptors for the hormone on cell surfaces.
When injected into newborn mice, EGF elicits the prolifera-
tion and differentiation of the epidermis (Cohen, 1983). In
tissue culture, EGF induces the proliferation of a wide
variety of cell types, including keratinocytes and transformed
epithelial cells (Carpenter & Cohen, 1979).
EGF receptor (EGFr) has three parts, an external domain,
a transmembrane portion and an internal domain. On
binding with its receptor, EGF leads to activation of a
tyrosine kinase on the internal domain of the receptor
(Carpenter & Cohen, 1979), a property shared with the
protein product of some oncogenes. Indeed the erb-B
oncogene product is a truncated EGFr (Downward et al.,
1984). The receptor is also internalised after stimulation.
Peptide growth factors produced by transformed cells
include transforming growth factor oc (TGF-ax), which is
structurally related to EGF and binds to the EGF receptor
(EGFr) (Marquardt et al., 1983) and transforming growth
factor (TGF,B) which binds to different receptors but is
synergistic with TGFax (Marquardt et al., 1983).
In breast cancer, it has been shown that the level of EGFr
is associated with metastatic potential, with poorly
differentiated tumours and with a poor prognostic subgroup
(Sainsbury et al., 1985a). The level of EGFr is also associated
with the degree of invasion and poor differentiation of
bladder cancer (Neal et al., 1985). EGFr have been found on
NSCLC cell lines grown in cell culture (Sherwin et al., 1981).
We have therefore examined lung tumours for the presence
of EGFr and investigated the relationship between receptor
density, histological subtype and tumour staging. We have
examined the relationship of the presence of EGFr on these
tumous with prognostic variables such as the degree of
differentiation of the tumours.
We used a monoclonal antibody to the receptor in an
immunoperoxidase technique (DeLellis et al., 1979).
Patients and methods
We studied tumour material from 77 patients (53 male and
24 female) undergoing surgery or diagnostic bronchoscopy.
The mean age of the patients was 60.4 years. Tumours were
staged by the tumour nodal involvement metastasis (TNM)
system on examination of the resected material. Tumours
with distant metastases or mediastinal nodes are graded
stage three, as also are tumours extending into the parietal
pleura or involving a main bronchus less than two
centimetres from the carina, or any tumour associated with
atalectasis or obstructive pneumonitis of an entire lung or
pleural effusion,
Forty patients had squamous tumours, of whom 17 had
stage three tumours. Twenty patients had adenocarcinomas
(six stage three), 13 had large cell undifferentiated carcinomas
(five stage three) and four tumours had features of both
adeno and squamous carcinomas, two of which were stage
three.
Lung tumour samples from operation were frozen in liquid
nitrogen in 71 of the patients within 30 minutes of resection.
Blocks of tissue were taken from different areas of the
tumour and 13 dual samples tested for the presence of EGFr.
Six tumour specimens were similarly obtained at
bronchoscopy.
The presence of EGFr was also assessed in samples of
uninvolved lung in 17 cases and in one sample from a
patient without malignancy. Samples of normal bronchus
were tested for EGFr in 8 patients.
The EGF receptor was identified by means of an indirect
immunoperoxidase technique (DeLeMis et al., 1979) with a
murine monoclonal antibody (EGFR1) (gift of Dr M.
Waterfield). The antibody was raised from an epidermoid
carcinoma cell line (A431) which expresses a high concentra-
tion of EGF receptors (Waterfield et al., 1982).
Five um cryostat sections were cut and picked up on
lysine-coated slides. After drying with a fan for 30min, they
were fixed in acid for 20min and washed twice for 5 min in
saline buffered to pH 7.6 with tris-HCl. The sections were
then covered with normal serum (diluted 1:4 with tris-
buffered saline) as a blocking agent for 10min. The sections
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were incubated at room temperature with primary antibody
for 30min. After two washes in tris-buffered saline, the
blocking step was repeated. The sections were then incubated
with peroxidase-conjugated rabbit anti-mouse immuno-
globulin (Dakopatts) for 30min. After two further 5-min
washes, peroxidase activity was developed by means of a
solution of diaminobenzidine. The sections were washed in
water, counterstained with haemaoxylin, dehydrated and
mounted. The positive control was human placenta, which
contains large numbers of EGFr. For negative controls we
omitted the primary antibody. Controls used in each run
showed similar intensity of staining.
The intensity of staining was assessed by two observers
reading the sections independently without knowledge of the
tumour stage or degree of differentiation. The sections were
graded on a scale from 0 to + + + according to the intensity
of staining of malignant cells relative to the positive control.
The placental control stained strongly positively on all
occasions and showed no staining when the primary
antibody was omitted. The histological typing of the tumours
was carried out on paraffin sections of the resected material.
Statistical analysis was performed using the chi-square test
on a two by four table of results.
Results
Normal lung and bronchus EGFr
Results of staining for EGFr in 17 specimens of normal lung
showed no staining in 5 specimens and mild staining (1+) in
9. Only two specimens of normal lung tissue showed
moderate staining graded + +, while one specimen had
strong staining for EGFr. In normal bronchial epithelium
there was strong positive staining for EGFr in a thin band in
the basal layer (Figure 1) and weaker staining in bronchial
glands.
Figure 1 Immunoperoxidase staining for EGFr in normal
bronchial tissue showing strong positive staining in the basal
layer. (x 240)
Carcinoma EGFr -Relation to histological type and stage
Staining in cancer specimens was significantly stronger in
tumour than in normal lung tissue (X2 =8.47, P<0.01). The
results for staining for EGFr in tumours are snown in Table
I, and illustrated in Figure 2. Staining in sections from
different parts of the tumour showed a good correlation of
intensity of EGFr staining in 10 cancers examined. Eight of
10 tumours examined had identical grading from different
ar_ea. aN tumour grAde EGFr ngate was the-n g.rad.ed
positive but one tumour which graded positive was
subsequently negative.
Twenty-seven of forty squamous tumours stained
moderately strongly or strongly (+ + or + + +), while only
nine of twenty adenocarcinomas stained similarly. Overall,
the staining in squamous tumours was significantly stronger
Figure 2 Immunoperoxidase staining for EGFr in a squamous
lung cancer. ( x 57). (a) primary antibody omitted; (b)
monoclonal primary antibody.
Table I EGFr in non-small cell lung cancer (normal lung
and bronchus)
Staining grade
O 1 2 3 Total
NSCLC
Squamous 5 8 13 14 40
Adeno 6 5 8 1 20
Large cell 4 3 5 1 13
Adenosquamous 0 1 2 1 4
Lung 5 9 2 1 17
Bronchus 2 5 0 0 7
Table II EGFr staining re tumour stage
Staining grade
O 1 2 3 Total
Stages 1 and 2 14 7 17 9 47
Stage 3 1 10 11 8 30
than for other NSCLC (X2=8.88, P<0.05). When all the
tumours were grouped according to stage there was signifi-
cantly stronger staining in the 30 stage three tumours
compared to 47 stage one and stage two tumours (X2 =9.87,
P<0.05) (Table II). There was no significant difference in the
number of stage three squamous tumours (17/40) compared
to the number of stage three adeno and large cell carcinomas
(13/37) (X2 =0.44) (Table III).
When all the tumours were divided according to degree of
differentiation (well and moderately differentiated versusEGF RECEPTORS IN NON-SMALL CELL LUNG CANCER 515
Table III Relation of stage to histological
subtype
Squamous Non-squamous
Stages I and II 23 24
Stage III 17 13
40 37
NS (X2=0.44).
poorly differentiated), there was no significant difference in
intensity of staining for EGFr between the groups. Likewise
squamous tumours alone showed no significant relationship
between EGFr score and degree of differentiation, although
there were only two well differentiated squamous tumours.
There was no statistically significant difference in the degree
of differentiation in different stages of tumour spread.
Discussion
We have demonstrated the presence of epidermal growth
factor receptors in non-small cell lung cancer and the fact
that squamous carcinomas show more staining than non-
squamous tumours. We have also shown that the intensity of
staining for EGFr is related to the stage of spread of the
tumours.
The histology of NSCLC can vary throughout the tumour
(Mountain et al., 1974) and thus we have taken samples from
different areas of the tumours and found no significant
variation of staining within tumours.
Hendler and Ozanne (1984) demonstrated EGFr in 11
squamous lung cancers. They showed that 7 of 8 adeno-
carcinomas failed to stain for EGFr, using a semiquantitative
autoradiography technique. The greater intensity of staining
for EGFr in squamous tumours is consistent with the
findings that squamous tumours at other sites, such as head
and neck or cervical cancer, and squamous carcinoma cell
lines express more EGF receptors than other cancers
(Cowley et al., 1984). Ozanne et al. have shown a 2 to 10-
fold excess of receptor sites in squamous cancers of various
sites, including lung, compared to normal skin (Gusterson et
al., 1984).
In our series, normal lung showed far less staining for
EGFr, and only 1/17 normal lungs were strongly positive.
This may reflect individual variation or possibly EGFr
involvement in other chronic inflammatory processes.
Our results suggest that epidermal growth factor receptor
may play a part in the genesis or spread of lung cancers.
This is the third common primary carcinoma in which we
have found a correlation of the presence of EGFr with some
of the prognostic features (Neal et al., 1985; Sainsbury et al.,
1985b). This may suggest that, rather than EGFr being
involved in tumour initiation, subclones of tumours that
express more EGFr or have had rearrangement of EGFr
genomic DNA may be selected for growth, invasion and
metastasis. This may be a relatively late change in tumour
development.
Cerny et al. (1986) examined 63 lung tumours, mainly
bronchial biopsies, and found 86% of squamous cancers
stained positively for EGFr, but none of 15 small cell
tumours stained. However, only 5 adenocarcinomas or large
cell tumours were examined and the relation to stage was
not assessed.
Neal et al (1985) showed that staining for EGFr was
related to poor differentiation of bladder cancers, and
Sainsbury et al. (1985b) found a similar relationship in breast
cancers, but we did not observe this in our specimens. In our
series of bronchial tumours, there was no significant
association of differentiation with stage and this may be a
reflection of the large proportion of tumours that were
moderately or poorly differentiated. Indeed in adeno-
carcinoma of the bronchus there is no significant survival
difference as regards degree of differentiation (Katlic &
Carter, 1979).
The detection of normal basal cells in the bronchial
mucosa staining for EGFr, first reported by Gusterson et al.
(1984), suggests that these stem cells of the mucosa may
require EGF for proliferation and differentiation to normal
mucosal cells. If these cells are the site of transformation for
lung cancers, it would be expected that some adeno-
carcinomas and large cell tumours would also express EGFr,
as we have found, in contrast to Ozanne's group (Hendler &
Ozanne, 1984).
The demonstration of a high concentration of EGFr in the
worse prognosis NSCLC suggests a novel potential target for
therapy. To quantitate the binding characteristics, we have
assayed membranes from these primary tumours and have
found high affinity sites (Kd 1 x 10- molar) for EGF and
much higher numbers of receptors than breast cancers
(190fmolmg-' membrane protein versus 4-47 fmolmg-'
membrane protein) (Sainsbury et al., 1985a). EGF bound
drug would be expected to react specifically at these sites,
thus leading to higher concentration of drug in tumour than
in other tissue. Drugs linked to EGF should be more
selective than current therapies, particularly as receptor
stimulation is linked to internalisation, and squamous
tumours express several-fold more EGFr than reported for
other normal tissues, including normal keratinocytes (Ozanne
et al., 1985).
The monoclonal antibody used here recognises the external
domain of the EGFr, so this could also be used for targeting.
The relationship of EGFr to other prognostic features in
three common primary tumours shows that this type of drug
therapy might be generally applicable in patients in whom
there is little alternative therapy at present. We are currently
studying this approach in human non-small cell cancer lines.
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